Item request has been placed!
×
Item request cannot be made.
×
Processing Request
CD25 + FOXP3 + CD45RA - regulatory T-cell infiltration as a prognostic biomarker for endometrial carcinoma.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- معلومة اضافية
- المصدر:
Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
- بيانات النشر:
Original Publication: London : BioMed Central, [2001-
- الموضوع:
- نبذة مختصرة :
Background: Regulatory T (Treg) cells reportedly play crucial roles in tumor angiogenesis as well as antitumor immunity. In order to explore their therapeutic potential, we investigated the precise prognostic impact of Treg markers in endometrial carcinoma.
Methods: We performed multiplexed immunofluorescence and quantitative image analyses of CD25, FOXP3, CTLA4, and CD45RA in tumor specimens from 176 consecutive patients treated at our institution for primary endometrial carcinomas. Bioinformatics analyses were further conducted to corroborate the findings.
Results: High CD25 + , FOXP3 + , and CD25 + FOXP3 + CD45RA - stromal cell counts correlated with better overall survival (OS) (p = 0.00019, 0.028 and 0.0012) and MSI-high (p = 0.015, 0.016 and 0.047). High CD45RA + stromal cell count was associated with superficial myometrial invasion (p = 0.0038). Bioinformatics survival analysis by Kaplan-Meier plotter showed that high CD25, FOXP3, CTLA4, and CD45RA mRNA expressions correlated with better OS (p = 0.046, 0.00042, 0.000044, and 0.0022). Univariate and multivariate analyses with various clinicopathologic prognostic factors indicated that high CD25 + or CD25 + FOXP3 + CD45RA - stromal cell count was significant and independent for favorable OS (p = 0.0053 and 0.0015). We subsequently analyzed the correlations between the multiplexed immunofluorescence results and treatment-free interval (TFI) after primary chemotherapy in recurrent cases, finding no significant associations. Further analysis revealed that high ratio of CD25 + : CD8 + cell count or CD25 + FOXP3 + CD45RA - : CD8 + cell count correlated with longer TFI (p = 0.021 and 0.021).
Conclusion: The current observations suggest that the balance between CD25 + or CD25 + FOXP3 + CD45RA - cells and CD8 + cells, corresponding to promoting or inhibiting effect on tumor angiogenesis, affect tumor chemosensitivity leading to prognostic significance. CD25 + FOXP3 + CD45RA - effector Treg tumor infiltration may serve as a useful prognostic biomarker and a potential target for immunotherapeutic manipulation of tumor chemosensitivity by novel management for advanced/recurrent endometrial carcinomas.
(© 2024. The Author(s).)
- References:
BMC Cancer. 2020 Feb 17;20(1):127. (PMID: 32066405)
Gynecol Oncol. 2009 Jul;114(1):105-10. (PMID: 19411095)
Cancer Res. 2017 Nov 1;77(21):e108-e110. (PMID: 29092952)
EBioMedicine. 2022 May;79:104010. (PMID: 35477069)
Front Immunol. 2021 Dec 14;12:788431. (PMID: 34970268)
Gynecol Oncol. 2008 Aug;110(2):216-21. (PMID: 18533240)
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. (PMID: 30054281)
Genome Biol. 2016 Aug 22;17(1):174. (PMID: 27549193)
J Clin Invest. 2019 Jul 25;129(10):4350-4364. (PMID: 31343989)
Biomed Res Int. 2021 May 5;2021:2068023. (PMID: 34036097)
J Environ Pathol Toxicol Oncol. 2021;40(1):65-74. (PMID: 33639074)
Biosci Rep. 2021 Apr 30;41(4):. (PMID: 33782686)
Clin Cancer Res. 2016 Feb 15;22(4):813-20. (PMID: 26880610)
Am J Obstet Gynecol. 2011 Jun;204(6):535.e1-5. (PMID: 21481836)
CA Cancer J Clin. 2019 Jul;69(4):258-279. (PMID: 31074865)
Sci Transl Med. 2012 May 16;4(134):134ra62. (PMID: 22593175)
Pathol Res Pract. 2017 Oct;213(10):1251-1256. (PMID: 28935177)
Br J Cancer. 2013 Sep 17;109(6):1703-10. (PMID: 23949151)
J Immunol. 2010 Sep 15;185(6):3199-208. (PMID: 20720207)
Int J Gynaecol Obstet. 2023 Aug;162(2):383-394. (PMID: 37337978)
PLoS One. 2012;7(1):e30422. (PMID: 22276195)
Cancer Sci. 2019 Jul;110(7):2080-2089. (PMID: 31102428)
Immunol Med. 2022 Jun;45(2):94-107. (PMID: 34495808)
Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:92-6. (PMID: 24472691)
N Engl J Med. 2022 Feb 3;386(5):437-448. (PMID: 35045221)
Clin Dev Immunol. 2012;2012:925135. (PMID: 22474485)
Front Immunol. 2020 Nov 19;11:587460. (PMID: 33329567)
Cancer. 2010 Dec 1;116(23):5407-14. (PMID: 20737572)
Cancer. 2010 Dec 15;116(24):5777-88. (PMID: 20734397)
Nature. 2017 May 4;545(7652):98-102. (PMID: 28445461)
Chin Med J (Engl). 2012 Jun;125(12):2120-5. (PMID: 22884140)
Cancer Res. 2011 Feb 15;71(4):1263-71. (PMID: 21303976)
Viruses. 2023 Aug 25;15(9):. (PMID: 37766222)
Gynecol Oncol. 2016 Feb;140(2):226-33. (PMID: 26644264)
Sci Rep. 2015 Oct 14;5:15179. (PMID: 26462617)
Jpn J Clin Oncol. 2022 May 31;52(6):539-544. (PMID: 35349681)
Int J Nanomedicine. 2020 Mar 24;15:1983-1996. (PMID: 32308382)
Theranostics. 2020 Jan 1;10(2):910-924. (PMID: 31903159)
Acta Oncol. 2007;46(6):792-7. (PMID: 17653902)
J Med Internet Res. 2021 Jul 26;23(7):e27633. (PMID: 34309564)
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. (PMID: 32442275)
Cancer Immunol Immunother. 2011 Jul;60(7):909-18. (PMID: 21644034)
IUBMB Life. 2019 Jul;71(7):986-991. (PMID: 31066485)
Gynecol Oncol. 2014 Mar;132(3):599-605. (PMID: 24388919)
- Contributed Indexing:
Keywords: CD25; CD45RA; Endometrial carcinoma; FOXP3; Survival; Treg cell
- الرقم المعرف:
0 (Forkhead Transcription Factors)
0 (FOXP3 protein, human)
0 (Biomarkers, Tumor)
EC 3.1.3.48 (Leukocyte Common Antigens)
0 (Interleukin-2 Receptor alpha Subunit)
0 (IL2RA protein, human)
0 (CTLA-4 Antigen)
0 (CTLA4 protein, human)
- الموضوع:
Date Created: 20240904 Date Completed: 20240905 Latest Revision: 20241009
- الموضوع:
20241010
- الرقم المعرف:
PMC11373268
- الرقم المعرف:
10.1186/s12885-024-12851-0
- الرقم المعرف:
39232704
No Comments.